On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.
Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania
Episode Topics1:48 What’s the difference between the FDA and Centers for Medicare and Medicaid Services?
3:58 What is the purpose of sharing a proposal and allowing public comment after? Is it possible the proposal could change?
9:09 What are your key takeaways from the CMS proposal?
11:58 Who’s being charged the cost of the treatment if it is part of a clinical trial?
18:33 What does this decision, with its focus on research often occurring in major urban medical centers, mean for equity and access?
26:27 What is the future of Alzheimer’s disease research after the CMS decision?
Show NotesRead the Center for Medicare and Medicaid Services’s press release about the proposed coverage policy, view submitted public comments about the decision, and submit your own comment.
Learn more about Dr. Jason Karlawish’s work and writing at his website.
Listen to our four-part episode series with Dr. Jason Karlawish about his book, The Problem of Alzheimer’s, on our website (episode 1, episode 2, episode 3, episode 4).
Bonus Episode: Current Research into Frontotemporal Dementia
Understanding and Managing Frontotemporal Dementia
It Takes Two to Tango: The Importance of Amyloid and Tau in Cognitive Decline
What We Have Learned from the Wisconsin Registry for Alzheimer’s Prevention Study
Considerations for Caregivers in Indian Country
Early-onset Alzheimer’s Disease: What to Know and What to Expect
Palliative Care and Hospice Conversations for Dementia Patients, Families and Caregivers
Building the Brain: Finding the Cognitive Benefits of Physical Activity
When Good Becomes Bad: Researching the Impact of Neuroinflammation
The Power of Disclosure: How Explaining Risk of Alzheimer's Disease Impacts Life Afterward
Simple Steps to Reduce Fall Risk among Older Adults
The Evolving Definition of Alzheimer’s Disease
Telemedicine Reduces Emergency Room Visits for Dementia Patients
Safety Tips for the Aging Driver
A Guide to Developing Mind-Body Skills for Improved Brain Health and Wellness
Bank Supports Aging Customers with Dementia Friendly Training for Its Employees
Medication Management Tips for Seniors
Dementia Caregiver Turns Advocate for People with Alzheimer’s Disease
Battling Health Disparities in Aging Research and Care
Improving Care for an Aging Population through Innovative Nursing and Caregiver Programs
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks